Business News Australia experiences…….One of Australia’s top cannabis companies has at present acquired a Cannabis Research Cultivation Permit, permitting the corporate to begin testing the results of cannabis on cancer cells.
MGC Pharma (ASX: MXC) will now be capable of proceed with botanical research initiatives in collaboration with RMIT University which incorporates cultivating and breeding strains to check in opposition to cancer cells.
Cannabis strains shall be screened for anticancer exercise, initially focussing on melanoma and prostate cancers.
The firm says the research will leverage current MGC Pharma IP and can concentrate on figuring out new cannabinoids and formulation to seek out new therapies.
“The grant of a cannabis research cultivation permit is an important step forward for MXC in Australia as we continue to broaden the potential application of our phytocannabinoid derived medicinal products,” says MGX Pharma co-founder and managing director Roby Zomer.